Enzychem Lifesciences Announces the FDA Orphan Drug Designation Granted to EC-18 on Acute Radiation Syndrome (ARS)

Enzychem Lifesciences, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS).

• Source: china-pharmacy
• 604
• February 1, 2018